This company has been marked as potentially delisted and may not be actively trading. Cara Therapeutics (CARA) Insider Trading & Ownership Add Compare Share Share Insider Trades Stock AnalysisHeadlinesInsider TradesOwnershipSustainabilityTrendsBuy This Stock Cara Therapeutics (NASDAQ:CARA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage3.10%Number OfInsiders Buying(Last 3 Years)0Number OfInsiders Selling(Last 3 Years)5Amount OfInsider Selling(Last 3 Years)$419.98K Get CARA Insider Trade Alerts Want to know when executives and insiders are buying or selling Cara Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CARA Insider Buying and Selling by Quarter Cara Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/2/2024Christopher PosnerCEOSell109$27.00$2,943.00 4/5/2024Joana GoncalvesInsiderSell76$29.88$2,270.88 2/8/2024Christopher PosnerCEOSell988$19.08$18,851.04 2/8/2024Ryan D MaynardCFOSell152$19.08$2,900.16 2/8/2024Scott TerrillionInsiderSell215$19.08$4,102.20 2/1/2024Christopher PosnerCEOSell138$19.80$2,732.40 11/2/2023Christopher PosnerCEOSell105$43.92$4,611.60 8/3/2023Christopher PosnerCEOSell119$110.52$13,151.88 6/23/2023Frederique Ph.D. MenzaghiSVPSell83$126.36$10,487.88 6/23/2023Scott TerrillionInsiderSell68$126.36$8,592.48 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 5/5/2023Christopher PosnerCEOSell107$158.40$16,948.80 4/4/2023Frederique Ph.D. MenzaghiSVPSell75$176.76$13,257.00 4/4/2023Scott TerrillionInsiderSell68$176.76$12,019.68 2/2/2023Christopher PosnerCEOSell116$424.80$49,276.80 1/17/2023Joana GoncalvesInsiderSell62$389.16$24,127.92 12/21/2022Frederique Ph.D. MenzaghiSVPSell97$405.72$39,354.84 12/21/2022Joana GoncalvesInsiderSell83$405.72$33,674.76 11/16/2022Christopher PosnerCEOSell401$400.68$160,672.68 (Data available from 1/1/2013 forward) CARA Insider Trading Activity - Frequently Asked Questions Who is on Cara Therapeutics' Insider Roster? The list of insiders at Cara Therapeutics includes Christopher Posner, Frederique Ph.D. Menzaghi, Joana Goncalves, Ryan D Maynard, and Scott Terrillion. Learn more on insiders at CARA. What percentage of Cara Therapeutics stock is owned by insiders? 3.10% of Cara Therapeutics stock is owned by insiders. Learn more on CARA's insider holdings. Which Cara Therapeutics insiders have been selling company stock? The following insiders have sold CARA shares in the last 24 months: Christopher Posner ($29,138.04), Joana Goncalves ($2,270.88), Ryan D Maynard ($2,900.16), and Scott Terrillion ($4,102.20). How much insider selling is happening at Cara Therapeutics? Insiders have sold a total of 1,783 Cara Therapeutics shares in the last 24 months for a total of $38,411.28 sold. Cara Therapeutics Key ExecutivesMr. Christopher A. Posner (Age 54)President, CEO & Director Compensation: $1.15MMr. Ryan D. Maynard (Age 55)Chief Financial Officer Compensation: $670.7kDr. Derek T. Chalmers D.Sc. (Age 60)Ph.D., Co-Founder & Senior Advisor Compensation: $580.93kMr. Scott M. Terrillion (Age 61)Chief Compliance Officer, General Counsel & Corporate Secretary Compensation: $689.63kMr. Matthew MurphyManager of Investor Relations More Insider Trading Tools from MarketBeat Related Companies Invizyne Technologies Insider Buying Atara Biotherapeutics Insider Buying Werewolf Therapeutics Insider Buying Adverum Biotechnologies Insider Buying Pliant Therapeutics Insider Buying Immunic Insider Buying Coya Therapeutics Insider Buying Equillium Insider Buying Quince Therapeutics Insider Buying Acumen Pharmaceuticals Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Marvell Insiders Buy Shares—Should Investors Follow Suit?This Insider Just Made a Massive Bet on Transocean's ComebackInsider Sales Jump at Broadcom and CoreWeave: Red Flag Ahead?Oklo Insiders Sell! Oh No! This Is Why Investors Shouldn’t WorryTop Insider Buys and Sells From September: Buy, Sell, or Hold? This page (NASDAQ:CARA) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored3 Major A.I. Threats That Could Upend the U.S. EconomyThe media's calling Artificial Intelligence a "revolution," but for many Americans, the real impact might actu...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
